Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ECE1 | P42892 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508926 | 0.88 | MEN1 (0.35) | TERTSLC1A2ECE1 | |
| SCHEMBL13448309 | 0.87 | POLB (0.35) | HPGDSLC1A2POLB | |
| SCHEMBL12421897 | 0.86 | POLB (0.32) | POLB | |
| SCHEMBL2610533 | 0.85 | AKT1 (0.33) | TERTL3MBTL1ECE1 | |
| SCHEMBL12505905 | 0.83 | HTT (0.35) | POLB | |
| SCHEMBL2610530 | 0.81 | POLB (0.36) | SLC1A2POLB | |
| SCHEMBL11955679 | 0.80 | POLB (0.32) | SLC1A2POLBECE1 | |
| SCHEMBL11955673 | 0.76 | POLB (0.32) | POLB | |
| SCHEMBL10037571 | 0.74 | POLB (0.37) | HPGDSLC1A2POLB | |
| SCHEMBL13185397 | 0.74 | POLB (0.37) | HPGDSLC1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | ACACB 4370/4885HPGD 3470/4885TERT 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.